Urology Times Innovation Celebration Video Series - Episode 28
“LHRH therapies are not going away. They are the standard of care,” says E. David Crawford, MD.
As part of the Urology Times' 50th Anniversary Innovation Celebration, E. David Crawford, MD, discusses the development of luteinizing hormone-releasing hormone (LHRH) agonists and antagonists in prostate cancer. Crawford is a professor of urology at the University of California, San Diego.